This trial will enroll patients who have already tried other treatments and failed (group A) or who are at high risk of their lymphoma coming back after an autologous hematopoeitic stem cell transplant (group B).
1 Primary · 1 Secondary · Reporting Duration: 1 year
18 Total Participants · 1 Treatment Group
Primary Treatment: TAA-T cells · No Placebo Group · Phase 1
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: